Supplemental Figure 1. IGF-2 circumvents CP01-B02 antibody in vivo. Conditions were as described in Figure 2D. Matrigel plugs containing VEGF or VEGF+IGF-2 were implanted into mice. Mice were treated with CP01-B02 (20 mg/kg) day 1 and day 3. Angiogenesis was scored at day 7.